152 related articles for article (PubMed ID: 14586150)
1. Ifosfamide in the treatment of malignant epithelial ovarian tumors.
Lissoni AA; Fei F; Rossi R; Fruscio R; Villa A; Zani G
Oncology; 2003; 65 Suppl 2():59-62. PubMed ID: 14586150
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.
Markman M; Kennedy A; Sutton G; Hurteau J; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 1998 Aug; 70(2):272-4. PubMed ID: 9740704
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide in the treatment of ovarian cancer.
Markman M
Semin Oncol; 1996 Jun; 23(3 Suppl 6):47-9. PubMed ID: 8677449
[TBL] [Abstract][Full Text] [Related]
4. [Ifosfamide in pediatric malignancy--experiences in the Northern Israel Oncology Center].
Roguin A; Ben Arush MW; Higasi A; Kuten A
Harefuah; 1996 Apr; 130(8):511-4, 584. PubMed ID: 8765870
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer.
Dorval T; Soussain C; Beuzeboc P; Garcia-Giralt E; Jouve M; Livartowski A; Mosseri V; Palangié T; Scholl S; Sastre X; Pouillart P
J Infus Chemother; 1996; 6(1):47-9. PubMed ID: 8748008
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide and mesna in epithelial ovarian carcinoma.
Sutton G
Gynecol Oncol; 1993 Oct; 51(1):104-8. PubMed ID: 8244163
[TBL] [Abstract][Full Text] [Related]
8. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
[TBL] [Abstract][Full Text] [Related]
9. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide in the treatment of soft tissue sarcomas.
Connelly EF; Budd GT
Semin Oncol; 1996 Jun; 23(3 Suppl 6):16-21. PubMed ID: 8677442
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies.
Lopez AM; Ketchum M; Nichols H; Xu MJ; Peng YM; Dorr R; Alberts DS
Cancer Chemother Pharmacol; 2000; 46(5):411-5. PubMed ID: 11127946
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide in the adjuvant therapy of soft tissue sarcomas.
Frustaci S; De Paoli A; Bidoli E; La Mura N; Berretta M; Buonadonna A; Boz G; Gherlinzoni F
Oncology; 2003; 65 Suppl 2():80-4. PubMed ID: 14586155
[TBL] [Abstract][Full Text] [Related]
13. Role of ifosfamide in cervical cancer: an overview.
Buda A; Dell'Anna T; Signorelli M; Mangioni C
Oncology; 2003; 65 Suppl 2():63-6. PubMed ID: 14586151
[TBL] [Abstract][Full Text] [Related]
14. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide: new idications-new dose strength. Limited evidence of effectiveness.
Prescrire Int; 1998 Apr; 7(34):45-7. PubMed ID: 10183382
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapeutic management of soft tissue sarcoma.
Thornton K
Surg Clin North Am; 2008 Jun; 88(3):647-60, viii. PubMed ID: 18514704
[TBL] [Abstract][Full Text] [Related]
17. High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone.
Demetri GD
Semin Oncol; 1996 Jun; 23(3 Suppl 6):22-6. PubMed ID: 8677444
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.
Markman M; Hakes T; Reichman B; Lewis JL; Rubin S; Jones W; Almadrones L; Pizzuto F; Hoskins W
J Clin Oncol; 1992 Feb; 10(2):243-8. PubMed ID: 1732425
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide treatment of advanced ovarian cancer.
Yazigi R; Wild R; Madrid J; Arraztoa J
Obstet Gynecol; 1984 Feb; 63(2):163-6. PubMed ID: 6694809
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide in urologic cancer.
Boccardo F; Guglielmini P
Oncology; 2003; 65 Suppl 2():67-72. PubMed ID: 14586152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
